Gluten: Friend or Foe?

The gluten debate has become one of the most polarizing topics in nutrition and medicine. On one side, we hear that gluten is a toxic protein causing widespread inflammation and disease. On the other, mainstream voices dismiss gluten sensitivity as a fad, relevant only to the small percentage with celiac disease. As functional medicine practitioners, we know the truth lies in the nuanced middle ground, where individual biochemistry, gut health, and immune function converge to create highly personalized responses to this ubiquitous protein. So where does gluten truly stand in the spectrum of dietary components? The answer, as with most things in functional medicine, is: it depends.

Understanding Gluten Beyond the Binary

Gluten is a composite protein found primarily in wheat, barley, and rye. It consists of two main protein families: gliadins and glutenins. These proteins give dough its elastic quality and contribute to the texture of baked goods. While this makes gluten valuable for food manufacturing, these same properties make it particularly resistant to complete digestion in the human gastrointestinal tract.

The incomplete digestion of gluten produces peptide fragments that can interact with our intestinal lining and immune system in various ways (1). For some individuals, this interaction is benign. For others, it triggers a cascade of inflammatory responses that extend far beyond the gut.

The Spectrum of Gluten-Related Disorders

Rather than thinking of gluten reactions as binary, functional medicine recognizes a spectrum of gluten-related disorders (2). Celiac disease represents one end of this spectrum, an autoimmune condition affecting approximately 1% of the population worldwide, where gluten triggers an immune attack on the small intestine, leading to villous atrophy and malabsorption (3). The diagnostic criteria are well-established: positive serology including anti-tissue transglutaminase antibodies (tTG-IgA) and anti-endomysial antibodies (EMA-IgA), along with characteristic histological changes on duodenal biopsy showing villous atrophy.

Non-celiac gluten sensitivity (NCGS) occupies a murkier but increasingly recognized position on this spectrum. These patients experience reproducible symptoms upon gluten exposure without the autoimmune markers or intestinal damage seen in celiac disease. Prevalence estimates vary widely, ranging from 0.5% to 13% of the population (4). Research suggests NCGS may involve innate immune activation rather than adaptive immunity, with studies showing increased intestinal permeability and systemic immune activation in affected individuals (5,6).

The mechanisms likely involve multiple pathways: increased intestinal permeability, activation of the innate immune system through toll-like receptors, and possibly reactions to other wheat components beyond gluten itself, such as amylase-trypsin inhibitors (ATIs) and wheat germ agglutinin (7). A 2016 study published in Gut demonstrated that gluten exposure in NCGS patients triggered systemic immune activation and intestinal epithelial cell damage, even in the absence of celiac disease (5).

We also see wheat allergy, a classic IgE-mediated allergic response, and the emerging recognition of gluten ataxia, a neurological manifestation where gluten triggers antibodies that cross-react with cerebellar Purkinje cells (8).

The Intestinal Permeability Connection

One of the most significant insights from functional medicine research is the relationship between gluten and intestinal permeability. Zonulin, a protein that modulates tight junctions between intestinal epithelial cells, increases in response to gliadin exposure (9). Dr. Alessio Fasano's groundbreaking research demonstrated that gliadin binding to the CXCR3 chemokine receptor triggers zonulin release, which in turn increases intestinal permeability by disassembling tight junction proteins (10). This occurs regardless of whether someone has celiac disease, though the degree and clinical significance vary among individuals.

Increased intestinal permeability allows larger molecules, including partially digested food proteins, bacterial lipopolysaccharides (LPS), and other antigenic material, to cross the intestinal barrier. This can trigger systemic immune activation and inflammation, potentially contributing to conditions far removed from the digestive tract: autoimmune diseases, neurological symptoms, skin conditions, and metabolic dysfunction (10,11).

For patients with compromised gut integrity from factors like chronic stress, dysbiosis, infections, medications (particularly NSAIDs and proton pump inhibitors), or environmental toxins, gluten may act as an additional stressor that tips the system toward dysfunction. In these cases, gluten isn't necessarily the primary cause of their condition but rather a contributing factor that perpetuates the inflammatory cycle.

Beyond Gluten: The Wheat Problem

An important consideration in functional medicine is that wheat contains more than just gluten. Modern wheat has been bred for higher yields and baking quality, resulting in changes to its protein composition and the introduction of higher levels of certain compounds.

Amylase-trypsin inhibitors (ATIs) are proteins that make up about 2-4% of wheat protein and activate the toll-like receptor 4 (TLR4) innate immune pathway, triggering inflammatory responses in the intestinal mucosa and potentially systemically (7). A 2017 study in Gastroenterology showed that ATIs contribute to intestinal inflammation and may be responsible for some symptoms attributed to gluten in NCGS patients (12).

Wheat germ agglutinin (WGA) is a lectin that can bind to intestinal epithelial cells and may contribute to gut barrier dysfunction and inflammatory responses. FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols), particularly fructans, are present in wheat at significant levels and can cause digestive symptoms in individuals with irritable bowel syndrome or small intestinal bacterial overgrowth. A landmark 2013 study by Biesiekierski et al. in Gastroenterology found that many patients who believed they were sensitive to gluten actually responded to FODMAPs rather than gluten itself (13).

This complexity explains why some patients feel better eliminating all wheat products, even when gluten-free alternatives that still contain wheat starch don't provide the same relief.

The Case for Individual Assessment

Given this complexity, the functional medicine approach focuses on individual assessment rather than universal recommendations. Not everyone needs to avoid gluten. For individuals with robust gut health, balanced microbiomes, and no inflammatory conditions, moderate gluten consumption is likely well-tolerated and poses no particular health risk.

However, several populations may benefit from gluten elimination or significant reduction. Those with diagnosed celiac disease require strict, lifelong avoidance—even small amounts (50mg daily, roughly 1/100th of a slice of bread) can cause intestinal damage (14). Patients with autoimmune conditions may benefit from elimination, as molecular mimicry between gliadin peptides and various tissue antigens may perpetuate autoimmune processes. The connection between gluten and thyroid autoimmunity is particularly well-documented, with multiple studies showing higher prevalence of celiac disease in patients with autoimmune thyroid disease and vice versa (15).

Individuals with chronic inflammatory conditions, whether manifesting as joint pain, skin issues, or systemic inflammation, often see improvement with gluten elimination. Those with neurological symptoms including brain fog, peripheral neuropathy, ataxia, or migraine headaches may experience benefit, as gluten can affect the nervous system through multiple mechanisms including neuroinflammation and production of anti-neuronal antibodies (8,16).

Patients with digestive complaints, particularly those with suspected increased intestinal permeability or IBS, often improve when gluten is removed while underlying gut dysfunction is addressed (17).

The Diagnostic Approach

From a functional medicine perspective, assessment should be thorough and individualized. Standard celiac screening with tissue transglutaminase IgA (tTG-IgA) and total IgA remains the first-line approach, but we often expand testing to include deamidated gliadin peptide antibodies (DGP-IgA and IgG), which show higher sensitivity particularly in children and may be positive when tTG is negative.

Anti-gliadin antibodies (AGA IgA and IgG) lack specificity for celiac disease but may be elevated in NCGS. Genetic testing for HLA-DQ2 and HLA-DQ8 has a 99% negative predictive value for celiac disease—if these genes are absent, celiac disease is virtually excluded (18). However, approximately 30-40% of the general population carries these genes, so their presence alone doesn't confirm celiac disease.

Markers of intestinal permeability such as serum zonulin can provide insight into gut barrier function, though interpretation requires careful clinical correlation. Comprehensive stool analysis can reveal dysbiosis, markers of inflammation like fecal calprotectin, and digestive function through elastase and other markers.

Importantly, an elimination and rechallenge protocol remains one of the most valuable diagnostic tools. Remove gluten completely for 30 to 90 days (long enough for antibodies to decrease and inflammation to resolve), then systematically reintroduce it while monitoring symptoms. This provides personalized, clinically relevant information that laboratory testing alone cannot offer (19). Critical consideration: All celiac testing must be performed while the patient is consuming gluten. Testing after gluten elimination can yield false negatives.

The Reintroduction Question

A common question in functional medicine practice is whether gluten can be reintroduced after a period of elimination. For celiac patients, the answer is clear: no. Even small amounts cause intestinal damage, and strict adherence to a gluten-free diet is required lifelong (14). Studies using video capsule endoscopy have shown that even patients who feel asymptomatic on a gluten-free diet may have persistent intestinal inflammation if they're consuming trace amounts of gluten.

For those with non-celiac gluten sensitivity, the answer depends on several factors. If symptoms were driven primarily by underlying gut dysfunction such as dysbiosis, infections like SIBO, or compromised intestinal integrity, and these issues have been successfully addressed, some individuals may tolerate gluten reintroduction in moderate amounts. However, if symptoms return upon rechallenge, this suggests either persistent underlying dysfunction or a more permanent sensitivity.

Many patients find that after healing their gut through a comprehensive protocol addressing the "5R" framework (Remove, Replace, Reinoculate, Repair, Rebalance), they can tolerate occasional gluten exposure without significant symptoms but feel best when it remains a minor rather than major part of their diet. This middle ground often represents a sustainable, realistic approach for long-term health.

Clinical Considerations

When working with patients around gluten, several practical considerations emerge. Quality matters significantly. Ancient grain varieties like einkorn and emmer contain different gluten protein profiles and may be better tolerated by some individuals, though they're not safe for celiac patients. Traditional sourdough preparations that allow for longer fermentation (at least 24 hours) can partially break down gluten proteins through bacterial proteolysis and reduce FODMAP content through fermentation (20).

Context is equally important. A patient under significant stress, dealing with acute illness, or experiencing gut dysfunction may react to gluten even if they typically tolerate it. This suggests that immune tolerance to gluten can be situational and dependent on overall physiological state, including factors like stress hormones, microbiome composition, and systemic inflammation.

We must also address the potential downsides of gluten-free diets. Many gluten-free processed foods are nutritionally inferior, higher in sugar and refined starches, and lower in fiber compared to their gluten-containing counterparts (21). Patients may become deficient in B vitamins (particularly folate, thiamin, and niacin), iron, calcium, vitamin D, and fiber if they don't choose whole-food alternatives or fortified gluten-free products (22).

Additionally, some research suggests that long-term gluten-free diets in people without celiac disease may be associated with increased cardiovascular risk, possibly due to reduced whole grain intake (23). The psychological burden and social limitations of strict dietary restrictions should be weighed against the clinical benefits. For some, the stress of rigid dietary restriction may outweigh the benefits of gluten elimination.

The Bigger Picture

In functional medicine, gluten is rarely the sole focus of treatment. It exists within a broader context of dietary quality, gut health, immune function, and overall inflammatory burden. A patient eating an otherwise poor diet high in processed foods, sugar, and industrial seed oils won't suddenly achieve optimal health simply by removing gluten. Conversely, a patient eating a nutrient-dense, whole-foods diet rich in vegetables, healthy fats, quality proteins, and diverse plant fibers may tolerate moderate gluten consumption without issue.

The question isn't whether gluten is universally good or bad, but rather how it fits into each individual's unique biochemistry, health status, and health goals. For some, it's a significant inflammatory trigger that stands between them and wellness. For others, it's a benign dietary component that can be enjoyed without consequence.

Moving Forward

As functional medicine practitioners, our role is to help patients navigate this complexity through evidence-based assessment, thoughtful elimination trials, attention to overall gut health and inflammatory status, and honest discussion about the benefits and challenges of gluten elimination. We should avoid both dismissing patient concerns and creating unnecessary dietary anxiety.

The gluten question offers an opportunity to practice truly personalized medicine, moving beyond the one-size-fits-all approaches that characterize much of conventional dietary advice. By meeting each patient where they are, assessing their individual situation through appropriate testing and clinical trials, and providing guidance based on their unique response, we can help them make informed decisions about whether gluten is a friend, foe, or something in between.

In the end, the most powerful question we can ask isn't "Is gluten bad?" but rather "How does gluten affect you, specifically, in the context of your current health status and goals?" The answer to that question, discovered through careful assessment and self-experimentation, provides the foundation for truly personalized nutrition and lasting wellness.

References

1. Shan L, Molberg Ø, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297(5590):2275-2279.
2. Sapone A, Bai JC, Ciacci C, et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012;10:13.
3. Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823-836.
4. Catassi C, Elli L, Bonaz B, et al. Diagnosis of non-celiac gluten sensitivity (NCGS): the Salerno Experts' Criteria. Nutrients. 2015;7(6):4966-4977.
5. Uhde M, Ajamian M, Caio G, et al. Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease. Gut. 2016;65(12):1930-1937.
6. Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol. 2012;107(12):1898-1906.
7. Junker Y, Zeissig S, Kim SJ, et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med. 2012;209(13):2395-2408.
8. Hadjivassiliou M, Sanders DS, Grünewald RA, Woodroofe N, Boscolo S, Aeschlimann D. Gluten sensitivity: from gut to brain. Lancet Neurol. 2010;9(3):318-330.
9. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151-175.
10. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci. 2012;1258:25-33.
11. Fasano A. Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol. 2012;42(1):71-78.
12. Zevallos VF, Raker V, Tenzer S, et al. Nutritional wheat amylase-trypsin inhibitors promote intestinal inflammation via activation of myeloid cells. Gastroenterology. 2017;152(5):1100-1113.
13. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145(2):320-328.
14. Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007;85(1):160-166.
15. Ch'ng CL, Jones MK, Kingham JG. Celiac disease and autoimmune thyroid disease. Clin Med Res. 2007;5(3):184-192.
16. Jackson JR, Eaton WW, Cascella NG, Fasano A, Kelly DL. Neurologic and psychiatric manifestations of celiac disease and gluten sensitivity. Psychiatr Q. 2012;83(1):91-102.
17. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144(5):903-911.
18. Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patients not carrying the DQA105-DQB102 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol. 2003;64(4):469-477.
19. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011;106(3):508-514.
20. Di Cagno R, De Angelis M, Auricchio S, et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerable in celiac sprue patients. Appl Environ Microbiol. 2004;70(2):1088-1096.
21. Missbach B, Schwingshackl L, Billmann A, et al. Gluten-free food database: the nutritional quality and cost of packaged gluten-free foods. PeerJ. 2015;3:e1337.
22. Vici G, Belli L, Biondi M, Polzonetti V. Gluten free diet and nutrient deficiencies: a review. Clin Nutr. 2016;35(6):1236-1241.
23. Lebwohl B, Cao Y, Zong G, et al. Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: prospective cohort study. BMJ. 2017;357:j1892.